Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 18/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.73 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8344775 | 0.95 | ELANE (0.82) | ELANECYP2C9CYP3A4 | |
| SCHEMBL8340908 | 0.95 | ELANE (0.82) | ELANECYP2C9CYP3A4 | |
| SCHEMBL13378082 | 0.93 | ELANE (0.67) | ELANECYP2C9CYP3A4 | |
| SCHEMBL13378054 | 0.90 | ELANE (0.75) | ELANECYP2C9CYP3A4CYP2C8CYP2C19 | |
| SCHEMBL13378086 | 0.90 | ELANE (0.67) | ELANECYP2C9CYP3A4 | |
| SCHEMBL13378063 | 0.89 | ELANE (0.91) | ELANECYP2C9CYP3A4 | |
| SCHEMBL13378060 | 0.88 | ELANE (0.65) | ELANECYP2C9CYP3A4LMNA | |
| SCHEMBL8344162 | 0.88 | ELANE (0.74) | ELANECYP2C9CYP3A4 | |
| SCHEMBL8340888 | 0.87 | ELANE (0.64) | ELANECYP2C9CYP3A4 | |
| SCHEMBL13378079 | 0.87 | ELANE (0.76) | ELANECYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691854-B2 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691854-B2 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-06 | — | — | US | disclosed |
| EP-1537081-B1 | DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | US | disclosed |
| WO-2004020412-A1 | DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | SERPINB1, ELANE, MPO | ELANE 2/4885CYP2C9 2483/4885CYP3A4 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.